These results collectively suggest that DPYSL2 upregulation is closely associated with tumorigenesis and tumor progression in bladder cancer and may present as a diagnostic and prognostic biomarker for bladder cancer. Here, DPYSL2 is linked to urinary bladder carcinoma.